An illustration of a chromosome unwinding to reveal its core structures including chromatin and DNA, which are often regulated by epigenetic marks

Beyond the genetic code, epigenetic changes profoundly impact health and the development of diseases like cancer.

credit: jerry mensah

Epigenetic cancer therapy: Targets and strategies

Epigenetic events shape cancer initiation and progression. By targeting mechanisms involved in epigenetic regulation, epigenetic therapeutics serve as effective weapons against cancer.
Yuning Wang
| 2 min read

Download the infographic here

Epigenetic cancer therapy: Targets and strategies
Illustrated by Jerry Mensah

Inhibiting histone deacetylation

Histone deacetylases (HDACs) remove acetyl groups from histone lysine residues, leading to closed chromatin structures and gene silencing. HDAC mutations aberrantly deacetylate or inactivate tumor suppressor genes that slow cell division, promoting cancer development (1). HDAC inhibitor drugs upregulate tumor suppressor genes and inhibit cancer cell growth. 

Targeting DNA methylation

DNA methylation by DNA methyltransferases (DNMTs) blocks transcriptional factor binding and disrupts gene activity, triggering many cancer types. DNMT blockade drugs effectively prevent DNA hypermethylation and inhibit tumor progression (2).

Modifying histone methylation

Lysine-specific histone demethylase 1 (LSD1), enhancer of zeste homolog 2 (EZH2), and disruptor of telomeric silencing 1-like (DOT1L) selectively methylate or demethylate specific histone lysine residues, regulating histone-DNA interactions and assorted cellular processes. LSD1, EZH2, or DOT1L overexpression causes cancer, making their inhibitors promising potential therapeutics (1).

Changing RNA modification

As critical epigenetic modulators, noncoding RNAs undergo methylation modification mediated by methyltransferase-like protein 3 (METTL3), affecting RNA structures and functions. Changes to RNA methylation machinery influence tumor cell proliferation and differentiation (3). Reversing abnormal RNA methylation by targeting METTL3 represents a novel approach to cancer treatment. 

References

  1. Cheng, Y. et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Sig Transduct Target Ther  4, 1–39 (2019). 
  2. Hu, C., Liu, X., Zeng, Y., Liu, J. & Wu, F. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clinical Epigenetics  13, 166 (2021). 
  3. Yang, X. et al. Epigenetic modulations of noncoding RNA: a novel dimension of Cancer biology. Molecular Cancer  19, 64 (2020).

About the Author

  • Yuning Wang
    Yuning joined the custom content team at Drug Discovery News in June 2022. She earned her PhD in biochemistry from the University of Western Ontario. Yuning developed a passion for science communication during graduate school and began her career as a science writer in 2020.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue